Biotech Values

[DewDiligence]

TauRx has enrolled 300 patients in first phase-3 AD trial:

http://finance.yahoo.com/news/taurx-achieves-milestone-global-phase-184400536.html

The Phase 3 trials of a tau aggregation inhibitor target 'tau tangles' in the brain, and could provide the first definitive data on a tau-based treatment that dissolves the tangles and slows or halts Alzheimer's disease. The first study is evaluating the use of LMTX in over 800 patients with mild to moderate Alzheimer's over a 15-month treatment period. The second study is evaluating the use of LMTX in up to 700 patients with mild Alzheimer's over an 18-month treatment period.

Will they PR each increment of 100 enrolled patients?